Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Kynan Feeney"'
Autor:
Zev A. Wainberg, Kynan Feeney, Myung Ah Lee, Andrés Muñoz, Antonio Cubillo Gracián, Sara Lonardi, Baek-Yeol Ryoo, Annie Hung, Yong Lin, Johanna Bendell, J. Randolph Hecht
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background Pancreatic cancer has a poor prognosis and few choices of therapy. For patients with adequate performance status, FOLFIRINOX or gemcitabine plus nab-paclitaxel are preferred first-line treatment. 5-Fluorouracil (5-FU)–based ther
Externí odkaz:
https://doaj.org/article/c809c0afdb704a3eb3d12d2651572617
Autor:
Luis G. Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, Jaafar Bennouna, Michael Schenker, Ying Cheng, Oscar Juan-Vidal, Hideaki Mizutani, Alejo Lingua, Felipe Reyes-Cosmelli, Niels Reinmuth, Juliana Menezes, Jacek Jassem, Svetlana Protsenko, Eduardo Richardet, Enriqueta Felip, Kynan Feeney, Bogdan Zurawski, Aurelia Alexandru, Emmanuel de la Mora Jimenez, Shaker Dakhil, Shun Lu, Martin Reck, Thomas John, Nan Hu, Xiaoqing Zhang, Judi Sylvester, Laura J. Eccles, Diederik J. Grootendorst, David Balli, Jaclyn Neely, David P. Carbone
Publikováno v:
Scientia
Non–small cell lung cancer; Brain metastases; Somatic mutations Càncer de pulmó de cèl·lules no petites; Metàstasis cerebrals; Mutacions somàtiques Cáncer de pulmón de células no pequeñas; Metástasis cerebrales; Mutaciones somáticas Int
Autor:
Stephen John Clarke, Matthew Burge, Kynan Feeney, Peter Gibbs, Kristian Jones, Gavin Marx, Mark P Molloy, Timothy Price, William H H Reece, Eva Segelov, Niall C Tebbutt
Publikováno v:
PLoS ONE, Vol 15, Iss 3, p e0229900 (2020)
BackgroundIn spite of demonstrating prognostic and possibly predictive benefit in retrospective cohorts and meta-analyses of cancer populations, including colorectal cancer (CRC), prospective evaluation of the relationship between neutrophil to lymph
Externí odkaz:
https://doaj.org/article/cd2703a957b846b1ba3c1198c841daa4
Autor:
Yelena Y Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli, Tianshu Liu, Michael Schenker, Patricio Yanez, Mustapha Tehfe, Ruben Kowalyszyn, Michalis V Karamouzis, Ricardo Bruges, Thomas Zander, Roberto Pazo-Cid, Erika Hitre, Kynan Feeney, James M Cleary, Valerie Poulart, Dana Cullen, Ming Lei, Hong Xiao, Kaoru Kondo, Mingshun Li, Jaffer A Ajani
Publikováno v:
Future Oncology.
What is this summary about? This is a summary of the 1-year results of a clinical research study known as CheckMate 649 published in The Lancet in June 2021. The 2-year results on the participants' health and overall quality of life from the same stu
Autor:
Kohei Shitara, Jaffer A. Ajani, Markus Moehler, Marcelo Garrido, Carlos Gallardo, Lin Shen, Kensei Yamaguchi, Lucjan Wyrwicz, Tomasz Skoczylas, Arinilda Campos Bragagnoli, Tianshu Liu, Mustapha Tehfe, Elena Elimova, Ricardo Bruges, Thomas Zander, Sergio de Azevedo, Ruben Kowalyszyn, Roberto Pazo-Cid, Michael Schenker, James M. Cleary, Patricio Yanez, Kynan Feeney, Michalis V. Karamouzis, Valerie Poulart, Ming Lei, Hong Xiao, Kaoru Kondo, Mingshun Li, Yelena Y. Janjigian
Publikováno v:
Nature. 603:942-948
Standard first-line chemotherapy results in disease progression and death within one year in most patients with human epidermal growth factor receptor 2 (HER2)-negative gastro-oesophageal adenocarcinoma1–4. Nivolumab plus chemotherapy demonstrated
Autor:
Ricardo Bruges, Pamela Salman, Ruben Dario Kowalyszyn, M. Li, Lucjan Wyrwicz, Valerie Poulart, Michalis V. Karamouzis, Arinilda Silva Campos Bragagnoli, Roberto Pazo-Cid, Marcelo Garrido, Yelena Y. Janjigian, Tomasz Skoczylas, Lin Shen, Mustapha Tehfe, Kensei Yamaguchi, Ming Lei, Michael Schenker, Thomas Zander, H. Xiao, Erika Hitre, Kynan Feeney, Markus Moehler, Kaoru Kondo, Kohei Shitara, Patricio Eduardo Yanez, Tianshu Liu, Dana Cullen, James M. Cleary, Jaffer A. Ajani
Publikováno v:
The Lancet. 398:27-40
First-line chemotherapy for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma has a median overall survival (OS) of less than 1 year. We aimed to evaluate first-line
Autor:
Kynan Feeney, Warren Lance Joubert, Rodolfo Eduardo Bordoni, Sunil Babu, Sathiya Marimuthu, Bill Hipkin, Liping Huang, Rachel Tam, Mirelis Acosta Rivera
Publikováno v:
Journal of Clinical Oncology. 41:TPS278-TPS278
TPS278 Background: The standard of care (SoC) for first-line management of non-microsatellite instability-high/deficient mismatch repair (non-MSI-H/dMMR; also referred to as microsatellite-stable/proficient MMR) mCRC includes systemic chemotherapy an
Autor:
A. Vergnenegre, A. Alexandru, Hiroshi Sakai, Helena Linardou, Michael Schenker, Claudia Caserta, László Urbán, Judith Raimbourg, Jacobus A. Burgers, Arteid Memaj, Suresh S. Ramalingam, Matthew D. Hellmann, Randeep Sangha, Martin Reck, Julie R. Brahmer, Mariano Provencio, Ki Hyeong Lee, Sang-We Kim, Clarisse Audigier-Valette, Luis Paz-Ares, Yuichiro Ohe, Hossein Borghaei, Kenneth J. O'Byrne, L. Lupinacci, Phuong Tran, Jong Seok Lee, Makoto Nishio, Kynan Feeney, Masayuki Takeda, Enric Carcereny, Adam Pluzanski, F. E. Nathan, Carlos Gallardo, Judith Bushong, Keunchil Park, B. Zurawski, Tudor-Eliade Ciuleanu, Reyes Bernabe Caro, Gregory A. Otterson
Publikováno v:
Journal of Thoracic Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
[Introduction] In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater than or equal to 1% (primary end point) or less than 1% (prespecified desc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36f7125153a7a538998a341b2f60e83e
http://hdl.handle.net/10261/305831
http://hdl.handle.net/10261/305831
Autor:
Stephan B. Dreyer, Rosie Upstill-Goddard, Assya Legrini, Andrew V. Biankin, Nigel B. Jamieson, David K. Chang, Sarah Allison, Dario Beraldi, Euan Cameron, Susanna L. Cooke, Richard Cunningham, Stephan Dreyer, Paul Grimwood, Shane Kelly, John Marshall, Brian McDade, Elizabeth A. Musgrove, Donna Ramsay, Lisa Evers, Selma Rebus, Lola Rahib, Bryan Serrels, Colin J. McKay, Paul Westwood, Nicola Williams, Fraser Duthie, William Shen, Antonio Pea, Amber L. Johns, Anthony J. Gill, Lorraine A. Chantrill, Paul Timpson, Angela Chou, Marina Pajic, Tanya Dwarte, David Herrmann, Claire Vennin, Thomas R. Cox, Brooke Pereira, Shona Ritchiee, Daniel A. Reed, Cecilia R. Chambers, Xanthe Metcalf, Max Nobis, Gloria Jeong, Lara Kenyon, Ruth J. Lyons, Nicola Waddell, John V. Pearson, Ann-Marie Patch, Katia Nones, Felicity Newell, Pamela Mukhopadhyay, Venkateswar Addala, Stephen Kazakoff, Oliver Holmes, Conrad Leonard, Scott Wood, Sean M. Grimmond, Oliver Hofmann, Jaswinder S. Samra, Nick Pavlakis, Jennifer Arena, Hilda A. High, Ray Asghari, Neil D. Merrett, Amitabha Das, Peter H. Cosman, Kasim Ismail, Alina Stoita, David Williams, Allan Spigellman, Duncan McLeod, Judy Kirk, James G. Kench, Peter Grimison, Charbel Sandroussi, Annabel Goodwin, R. Scott Mead, Katherine Tucker, Lesley Andrews, Michael Texler, Cindy Forrest, Mo Ballal, David Fletcher, Maria Beilin, Kynan Feeney, Krishna Epari, Sanjay Mukhedkar, Nikolajs Zeps, Nan Q. Nguyen, Andrew R. Ruszkiewicz, Chris Worthley, John Chen, Mark E. Brooke-Smith, Virginia Papangelis, Andrew D. Clouston, Andrew P. Barbour, Thomas J. O’Rourke, Jonathan W. Fawcett, Kellee Slater, Michael Hatzifotis, Peter Hodgkinson, Mehrdad Nikfarjam, James R. Eshleman, Ralph H. Hruban, Christopher L. Wolfgang, Aldo Scarpa, Rita T. Lawlor, Vincenzo Corbo, Claudio Bassi
Publikováno v:
Gastroenterology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee9df49d92ea32ac7a1cf88268d4685b
http://hdl.handle.net/11562/1056899
http://hdl.handle.net/11562/1056899
Autor:
Luis G. Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo-Dols, Jaafar Bennouna, Ying Cheng, Hideaki Mizutani, Alejo Lingua, Felipe Reyes, Niels Reinmuth, Juliana Janoski De Menezes, Jacek Jassem, Svetlana Protsenko, Kynan Feeney, Emmanuel De La Mora Jimenez, Shun Lu, Tom John, David Paul Carbone, Xiaoqing Zhang, Nan Hu, Martin Reck
Publikováno v:
Journal of Clinical Oncology. 40:LBA9026-LBA9026
LBA9026 Background: In CheckMate 9LA (NCT03215706), 1L NIVO + IPI combined with 2 cycles of chemo was shown to provide survival benefit vs chemo alone in pts with metastatic NSCLC. Here, we report updated efficacy and safety with a 3-year minimum fol